RHHBY - Roche Holding AG

Other OTC - Other OTC Delayed price. Currency in USD
Show:
Balance sheet
Cash flow
Annual

Income statement

Currency in CHF. All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
64,383,000
63,281,000
62,801,000
58,323,000
61,466,000
Cost of revenue
20,642,000
20,397,000
19,647,000
16,177,000
18,351,000
Gross profit
43,741,000
42,884,000
43,154,000
42,146,000
43,115,000
Operating expenses
Research development
14,588,000
16,023,000
14,799,000
13,009,000
12,774,000
Selling general and administrative
13,100,000
12,530,000
13,249,000
12,614,000
15,078,000
Total operating expenses
24,116,000
25,408,000
24,999,000
23,603,000
25,567,000
Operating income or loss
19,625,000
17,476,000
18,155,000
18,543,000
17,548,000
Interest expense
511,000
690,000
419,000
553,000
791,000
Income before tax
18,496,000
16,327,000
17,398,000
17,965,000
16,614,000
Income tax expense
2,616,000
2,796,000
2,463,000
2,897,000
2,506,000
Income from continuing operations
15,880,000
13,531,000
14,935,000
15,068,000
14,108,000
Net income
14,657,000
12,421,000
13,930,000
14,295,000
13,497,000
Net income available to common shareholders
14,657,000
12,421,000
13,930,000
14,295,000
13,497,000
Basic EPS
-
-
2.05
2.09
1.97
Diluted EPS
-
-
2.02
2.06
1.95
Basic average shares
-
-
6,800,000
6,840,000
6,848,000
Diluted average shares
-
-
6,880,000
6,920,000
6,912,000
EBITDA
-
20,861,000
22,260,000
23,076,000
21,697,000